Overview: HB 6810, AN ACT REQUIRING TRANSPARENCY FROM HEALTH CARE ENTITIES THAT RECEIVE PRESCRIPTION DRUG DISCOUNTS, was referred to the Joint Committee on Human Services. It was introduced on January 29, 2025.
Purpose and Intent: The bill aims to increase transparency and accountability around the use of prescription drug discounts by health care entities that participate in Medicaid and other state-funded health care programs. The legislation seeks to ensure that the benefits of these discounts are being passed on to consumers and the state, rather than being retained by the health care providers.
Key Provisions:
- Requires health care entities that receive prescription drug discounts to report detailed information on the discounts, including the amounts received and how they were used
- Mandates the state to publish the reported information on a publicly accessible website
- Authorizes the state to impose penalties on health care entities that fail to comply with the reporting requirements
Affected Parties and Impacts:
- Health care entities, such as hospitals, clinics, and pharmacies, that participate in Medicaid and other state-funded health programs and receive prescription drug discounts
- Medicaid and other state health care program beneficiaries, who may see the benefits of the discounts reflected in their out-of-pocket costs
- The state government, which can use the reported information to ensure the proper use of prescription drug discounts and potentially realize cost savings
Procedural and Timeline Considerations:
The bill has been referred to the Joint Committee on Human Services for further consideration. If passed, the state would need to develop the reporting requirements and establish the public disclosure process, which could take several months to implement.